Literature DB >> 25477607

Response to "bupivacaine liposomal versus bupivacaine: comparative review".

E Richard Kessler1.   

Abstract

Entities:  

Year:  2014        PMID： 25477607      PMCID： PMC4252179          DOI： 10.1310/hpj4909-793

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


× No keyword cloud information.
  8 in total

1.  Evaluating therapeutic benefit in postsurgical analgesia requires global assessment: an example from liposome bupivacaine in hemorrhoidectomy.

Authors:  William K Schmidt; Gary Patou; Girish P Joshi
Journal:  Hosp Pract (1995)       Date:  2012-02

2.  A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty.

Authors:  Kenneth Bramlett; Erol Onel; Eugene R Viscusi; Kevin Jones
Journal:  Knee       Date:  2012-01-28       Impact factor: 2.199

3.  Liposomal bupivacaine versus traditional periarticular injection for pain control after total knee arthroplasty.

Authors:  Deren T Bagsby; Phillip H Ireland; R Michael Meneghini
Journal:  J Arthroplasty       Date:  2014-04-04       Impact factor: 4.757

4.  Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid-related adverse events and their impact on clinical and economic outcomes.

Authors:  E Richard Kessler; Manan Shah; Stephen K Gruschkus; Aditya Raju
Journal:  Pharmacotherapy       Date:  2013-04       Impact factor: 4.705

5.  An extended paIn relief trial utilizing the infiltration of a long-acting Multivesicular liPosome foRmulation Of bupiVacaine, EXPAREL (IMPROVE): a Phase IV health economic trial in adult patients undergoing ileostomy reversal.

Authors:  Jorge E Marcet; Valentine N Nfonsam; Sergio Larach
Journal:  J Pain Res       Date:  2013-07-18       Impact factor: 3.133

6.  Extended pain relief trial utilizing infiltration of Exparel(®), a long-acting multivesicular liposome formulation of bupivacaine: a Phase IV health economic trial in adult patients undergoing open colectomy.

Authors:  Stephen M Cohen
Journal:  J Pain Res       Date:  2012-11-20       Impact factor: 3.133

7.  Liposome Bupivacaine for Postsurgical Analgesia in Adult Patients Undergoing Laparoscopic Colectomy: Results from Prospective Phase IV Sequential Cohort Studies Assessing Health Economic Outcomes.

Authors:  Keith A Candiotti; Laurence R Sands; Edward Lee; Sergio D Bergese; Alan E Harzman; Jorge Marcet; Anjali S Kumar; Eric Haas
Journal:  Curr Ther Res Clin Exp       Date:  2013-12-27

8.  Liposome bupivacaine for improvement in economic outcomes and opioid burden in GI surgery: IMPROVE Study pooled analysis.

Authors:  Stephen M Cohen; Jon D Vogel; Jorge E Marcet; Keith A Candiotti
Journal:  J Pain Res       Date:  2014-06-24       Impact factor: 3.133
  8 in total
  1 in total

Review 1.  The Role of Exparel Plus Meloxicam for Postoperative Pain Management.

Authors:  Alan David Kaye; Matthew B Novitch; Sam F Carlson; Mitchell C Fuller; Shane W White; Alexander R Haroldson; Jennifer A Kaiser; Mohamed A Elkersh; Andrew J Brunk; George M Jeha; Elyse M Cornett
Journal:  Curr Pain Headache Rep       Date:  2020-01-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.